Skip to main content

Advertisement

SpringerLink
Log in

The tissue renin-angiotensin-aldosterone system in diabetes mellitus

  • Published:
Current Hypertension Reports Aims and scope Submit manuscript

Abstract

Diabetes is associated with an inordinate burden of cardiovascular and renal disease, which is expected to accelerate during the next few decades. The relationship between the renin-angiotensin system (RAS) and diabetic macrovascular and microvascular disease is well established. The contribution of the tissue RAS in disease pathogenesis has recently been the focus of much interest, and has prompted investigators to explore the use of high-dose RAS inhibition with monotherapy or combination therapy to provide a more complete blockade of the actions of angiotensin II, beyond lowering blood pressure. There is now evidence to support this approach to maximize cardiovascular and renal protection. Optimal dosing strategies remain uncertain, but tissue specificity does not appear to be important if the doses of angiotensin-converting enzyme-I and angiotensin-receptor binders are high enough. The purpose of this review is to highlight our current understanding of the role of the tissue RAS in the pathogenesis of diabetic end-organ damage and ongoing strategies to interfere pharmacologically.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References and Recommended Reading

  1. Harris M: Health care and health care status and outcomes for patients with type 2 diabetes. Diabetes Care 2000, 23:754–758.

    Article  PubMed  CAS  Google Scholar 

  2. US Renal Data System: USRDS 1999 Annual Data Report. Bethesda, MD: National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases; 1999:25–38.

    Google Scholar 

  3. Arauz-Pacheco C, Parrott MA, Raskin P: Treatment of hypertension in adults with diabetes. Diabetes Care 2003, 26:S80-S82.

    Article  PubMed  Google Scholar 

  4. Lewis EJ, Hunsicker LG, Clark WR, et al.: Renoprotective effects of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med 2001, 345:851–886. Large clinical trial demonstrating the superior risk reduction of hard renal end points using ARB versus calcium-blocker therapy in type 2 diabetes.

    Article  PubMed  CAS  Google Scholar 

  5. Brenner BM, Cooper ME, de Zeeuw D, et al.: Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med 2001, 345:861–869. Large clinical trial demonstrating significant reduction of hard renal end points with ARB therapy in type 2 diabetes.

    Article  PubMed  CAS  Google Scholar 

  6. Parving HH, Lehnert H, Brochner-Mortensen J, et al.: The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes. N Engl J Med 2001, 345:870–878. First trial to demonstrate dose-related renoprotective effects and reversal of proteinuria with ARB therapy in type 2 diabetics with microalbuminuria.

    Article  PubMed  CAS  Google Scholar 

  7. Heart Outcomes Prevention Evaluation (HOPE) Investigators: Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE substudy. Lancet 2000, 355:253–259. Substudy of HOPE demonstrating cardiovascular and renal protection with ACEI therapy in diabetics without proteinuria.

    Article  Google Scholar 

  8. Nakao N, Yoshimura A, Morita H, et al.: Combination treatment of angiotensin-II receptor blocker and angiotensinconverting-enzyme inhibitor in non-diabetic renal disease (COOPERATE): a randomized controlled trial. Lancet 2003, 361:117–124.

    Article  PubMed  CAS  Google Scholar 

  9. McMurray JJ, Ostergren J, Swedberg K, et al.: CHARM Investigators and Committees. Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function taking angiotensin converting-enzyme inhibitors: the CHARM-Added trial. Lancet 2003, 362:767–771.

    Article  PubMed  CAS  Google Scholar 

  10. Brunner HR, Gavras H, Waeber A: Oral angiotensin-converting enzyme inhibitor in long-term treatment of hypertensive patients. Ann Intern Med 1988, 2:1317–1325.

    Google Scholar 

  11. Dzau VJ, Bernstein K, Celermajer D, et al.: The relevance of tissue angiotensin-converting enzyme: manifestations in mechanistic and endpoint data. Am J Cardiol 1988, 88:1L-20L.

    Article  Google Scholar 

  12. Urata H, Nishmura H, Ganten D: Chymase dependent angiotensin II forming system in humans. Am J Hyperten 1996, 9:277–284.

    Article  CAS  Google Scholar 

  13. Sadoshima JI, Izumo S: Autocrine secretion of angiotensin II mediates stretch-induced hypertrophy of cardiac myocytes in vitro. Contrib Nephrol 1996, 118:214–221.

    PubMed  CAS  Google Scholar 

  14. Johnson CI: Tissue angiotensin-converting enzyme in cardiac and vascular hypertrophy. Hypertension 1994, 23:258–268.

    Google Scholar 

  15. Bell GM: Increased plasma atrial natriuretic factor and reduced plasma renin in patients with poorly controlled diabetes mellitus. Clin Sci 1989, 77:177–182.

    PubMed  CAS  Google Scholar 

  16. Bryer-Ash M, Fraze EB, Luetscher JA: Plasma renin and prorenin (inactive renin) in diabetes mellitus: effects of intravenous furosemide. J Clin Endocrinol Metab 1988, 66:454–458.

    Article  PubMed  CAS  Google Scholar 

  17. Naruse M, Wasada T, Naruse K, et al.: Pathophysiological significance of plasma total renin and prorenin in patients with diabetes mellitus. Endocr J 1995, 42:225–233.

    PubMed  CAS  Google Scholar 

  18. Everett AD, Scott J, Wilfong N, et al.: Renin and angiotensinogen expression during the evolution of diabetes. Hypertension 1992, 19:70–78.

    PubMed  CAS  Google Scholar 

  19. Anderson S: Role of local and systemic angiotensin in diabetic renal disease. Kidney Int 1997, 52:S107-S110.

    Google Scholar 

  20. De’Oliveira JM, Price DA, Fisher NDL, et al.: Autonomy of the renin system in type II diabetes: dietary sodium and renal hemodynamic responses to ACE inhibition. Kidney Int 1997, 52:771–777.

    Article  PubMed  CAS  Google Scholar 

  21. Price DA, Porter L, De’Oliveira JM, et al.: The paradox of the low renin state: hormonal and renal responses to an Ang II antagonist, irbesartan, in diabetic nephropathy. J Am Soc Nephrol 1996, 7:163–167.

    Google Scholar 

  22. Price DA, De’Oliveira JM, Fisher, et al.: The state and responsiveness of the renin-angiotensin-aldosterone system in patients with type II diabetes mellitus. Am J Hypertens 1999, 12:348–355.

    PubMed  CAS  Google Scholar 

  23. Price DA, Porter LE, Gordon M, et al.: The paradox of the low-renin state in diabetic nephropathy. J Am Soc Nephrol 1999, 10:2382–2391.

    PubMed  CAS  Google Scholar 

  24. Flack JM, Hamaty M, Staffileno BA: Renin angiotensin aldosterone kinin system influences on diabetic vascular disease and cardiomyopathy. Miner Electrolyte Metab 1998, 24:412–422.

    Article  PubMed  CAS  Google Scholar 

  25. Redgrave JE, Rabinowe SL, Hollenberg NK, et al.: Correction of abnormal renal blood flow response to angiotensin II by converting enzyme inhibition is essential hypertensives. J Clin Invest 1985, 75:1285–1290.

    Article  PubMed  CAS  Google Scholar 

  26. Moore T, Rich G, McKnight JA, et al.: Salt sensitivity of hypertension and response to angiotensin-converting enzyme inhibition with benazepril. Am J Hypertens 1995, 9:54–60.

    Article  Google Scholar 

  27. Weir MR: Impact of salt intake on blood pressure and proteinuria in diabetes: importance of the renin-angiotensin system. Miner Electrolyte Metab 1998, 24:438–445.

    Article  PubMed  CAS  Google Scholar 

  28. Lansang M, Hollenberg NK: Renal perfusion and the renal hemodynamic response to blocking the renin system in diabetes: Are the forces leading to vasodilation and vasoconstriction linked? Diabetes 2002, 51:2025–2028.

    Article  PubMed  CAS  Google Scholar 

  29. The CONSENSUS Trial Study Group: Effects of enalapril on mortality in severe congestive heart failure. Results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS). N Engl J Med 1987, 316:1429–1435.

    Article  Google Scholar 

  30. Cohn JN, Anand IS, Latini R, et al.: Sustained reduction of aldosterone in response to the angiotensin receptor blocker valsartan in patients with chronic heart failure: results from the Valsartan Heart Failure Trial. Circulation 2003, 108:1306–1309.

    Article  PubMed  CAS  Google Scholar 

  31. Duh E, Aiello LP: Vascular endothelial growth factor and diabetes: the agonist versus antagonist paradox. Diabetes 1999, 48:1899–1906.

    Article  PubMed  CAS  Google Scholar 

  32. Otani A, Takagi H, Oh H, et al.: Angiotensin II induces expression of the Tie2 receptor ligand, angiopoietin-2, in bovine retinal endothelial cells. Diabetes 2001, 50:867–875.

    Article  PubMed  CAS  Google Scholar 

  33. Moravski CJ, Kelly DJ, Cooper ME, et al.: Retinal neovascularization is prevented by blockade of the renin angiotensin system. Hypertension 2000, 36:1099–1104.

    PubMed  CAS  Google Scholar 

  34. Williams B, Baker AQ, Gallacher B, et al.: Angiotensin II increases vascular permeability factors gene expression by human vascular smooth muscle cells. Hypertension 1995, 25:913–917.

    PubMed  CAS  Google Scholar 

  35. Otani A, Takagi H, Suzuma K, et al.: Angiotensin II potentiates vascular endothelial growth factor-induced angiogenic activity in retinal microcapillary endothelial cells. Circ Res 1998, 82:619–628.

    PubMed  CAS  Google Scholar 

  36. Chaturvedi N, Sjolie AK, Stephenson JM, et al.: Effect of lisinopril on progression of retinopathy in normotensive people with type 1 diabetes. Lancet 1998, 351:28–31.

    Article  PubMed  CAS  Google Scholar 

  37. Border WA, Yamamoto T, Noble A: Transforming growth factor-beta in diabetic nephropathy. Diabetes Metab Rev 1996, 12:309–339.

    Article  PubMed  CAS  Google Scholar 

  38. Sharma K, Eltayeb BO, McGowen TA, et al.: Captopril-induced reduction of serum levels of transforming growth factor-beta1 correlates with long term renoprotection in insulin-dependent diabetic patients. Am J Kidney Dis 1999, 34:818–823.

    PubMed  CAS  Google Scholar 

  39. Houlihan CA, Akdeniz A, Tsalamandris C, et al.: Urinary transforming growth factor-beta excretion in patients with hypertension, type 2 diabetes, and elevated albumin excretion rate: effects of angiotensin receptor blockade and sodium restriction. Diabetes Care 2002, 25:1072–1077.

    Article  PubMed  CAS  Google Scholar 

  40. Lods N, Ferrari P, Frey F, et al.: Angiotensin-converting enzyme inhibition but not angiotensin II receptor blockade regulates matrix metalloproteinase activity in patients with glomerulonephritis. J Am Soc Nephrol 2003, 14:2861–2872.

    Article  PubMed  CAS  Google Scholar 

  41. Tikellis C, Johnston CI, Forbes JM, et al.: Characterization of renal angiotensin-converting enzyme 2 in diabetic nephropathy. Hypertension 2003, 41:392–397.

    Article  PubMed  CAS  Google Scholar 

  42. Peters H, Ritz E. Dosing angiotensin II blockers-beyond blood pressure. Nephrol Dial Transplant 1999, 14:2568–2570.

    Article  PubMed  CAS  Google Scholar 

  43. Leung PS, Carlsson PO: Tissue renin angiotensin system: its expression, localization, regulation and potential role in the pancreas. J Mol Endocrinol 2001, 26:155–164.

    Article  PubMed  CAS  Google Scholar 

  44. Carlsson PO, Berne C, Jansson L: Angiotensin II and the endocrine pancreas: effects on islet cell blood flow and insulin secretion in rats. Diabetologia 1998, 41:127–133.

    Article  PubMed  CAS  Google Scholar 

  45. The Captoprill Prevention Project (CAPP) Study Group: Effect of angiotensin-converting enzyme inhibition compared with conventional therapy on cardiovascular morbidity and mortality in hypertension: the Captopril Prevention Project (CAPP) randomized trial. Curr Hypertens Rep 1999, 1:466–467.

    Google Scholar 

  46. Dahlof B, Devereux RB, Kjeldsen SE, et al.: Cardiovascular morbidity and mortality in the Losartan Intervention for Endpoint reduction in hypertension (LIFE) study: a randomized trial against atenolol. Lancet 2002, 359:995–1003. First large trial to demonstrate primary stroke prevention in diabetics with ARB therapy.

    Article  PubMed  CAS  Google Scholar 

  47. Pfeffer MA, McMurray JJ, Valazquez EJ, et al.: Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both. N Engl J Med 2003, 349:1893–906.

    Article  PubMed  CAS  Google Scholar 

  48. Unger T: The ongoing telmisartan alone and in combination with ramipril (TRACE) global endpoint trial program. Am J Cardiol 2003, 91:28G-34G.

    Article  PubMed  Google Scholar 

  49. Ryden L, Armstrong PW, Cleland JG, et al.: Efficacy and safety of high dose lisinopril in chronic heart failure patients at high cardiovascular risk, including those with diabetes mellitus. Results from the ATLAS trial. Eur Heart J 2000, 21:1967–1978.

    Article  PubMed  CAS  Google Scholar 

  50. Barki-Harrington L, Luttrell LM, Rockman HA: Dual inhibition of beta-adrenergic and angiotensin II receptors by a single agonist: a functional role for receptor-receptor interaction in vivo. Circulation 2003, 30:1611–1618.

    Article  CAS  Google Scholar 

  51. Siragy HM, de Gasparo M, El-Kersh M, et al.: Angiotensinconverting enzyme inhibition potentiates angiotensin II type 1 receptor effects on renal bradykinin and cGMP. Hypertension 2001, 38:183–186.

    PubMed  CAS  Google Scholar 

  52. Zandbergen AA, Beggen MG, Lamberts SW, et al.: Effect of losartan on microalbuminuria in normotensive patients with type 2 diabetes mellitus. Ann Intern Med 2003, 139:90–96. Clinical trial demonstrating the impact of dose escalation for renoprotection in normotensive type 2 diabetics.

    PubMed  CAS  Google Scholar 

  53. Mogensen CE, Neldam S, Tikkanen I, et al.: Randomized, controlled trial of dual blockade on renin-angiotensin system in patients with hypertension, microalbuminuria, and noninsulin dependent diabetes: the candesartan and lisinopril microalbuminuria (CALM) study. BMJ 2000, 321:1440–1444.

    Article  PubMed  CAS  Google Scholar 

  54. Rossing K, Christensen PK, Jensen BR, et al.: Dual blockade of the renin-angiotensin system in diabetic nephropathy: a randomized double-blind crossover study. Diabetes Care 2002, 25:95–100.

    Article  PubMed  CAS  Google Scholar 

  55. Rossing K, Christensen PK, Hansen BV, et al.: Optimal dose of candesartan for renoprotection in type 2 diabetic patients with nephropathy: a double-blind randomized cross-over study. Diabetes Care 2003, 26:150–155.

    Article  PubMed  CAS  Google Scholar 

  56. Bakris GL, Weir MR, Shanifar S, et al.: Effects of blood pressure level on progression of diabetic nephropathy: results from the RENAAL Study. Arch Intern Med 2003, 163:1555–1656. This substudy of RENAAL demonstrates that those with the highest baseline blood pressure had the greatest cardiovascular risk, but their risk was reduced the most with blood pressure treatment to less than 140/90 mm Hg.

    Article  PubMed  Google Scholar 

  57. SMART (Supramaximal Doses of Atacand and Renal Therapy) Study. Wilmington, DE: AstraZeneca; 2003.

  58. DROP (Diovan Reduction of Proteinuria) Study. Basel, Switzerland: Novartis; 2003.

  59. Campbell R, Sangalli F, Perticucci E, et al.: Effects of combined ACE inhibitor and angiotensin II antagonist treatment in human chronic nephropathies. Kidney Int 2003, 63:1094–1103.

    Article  PubMed  CAS  Google Scholar 

  60. Adamczak M, Gross ML, Krtil J, et al.: Reversal of glomerulosclerosis after high dose enalapril treatment in subtotally nephrectomized rats. J Am Soc Nephrol 2003, 14:2833–2842. This study reveals a dramatic reversal of glomerulosclerosis, tubulointerstitial, and vascular injury by high-dose ACEI-induced glomerular remodeling.

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Renal Division, University of Maryland Hospital, N3W 143, 22 S. Greene Street, 21202, Baltimore, MD, USA

    Donna S. Hanes MD, Anita Nahar MD & Matthew R. Weir MD

Authors
  1. Donna S. Hanes MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Anita Nahar MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Matthew R. Weir MD
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Hanes, D.S., Nahar, A. & Weir, M.R. The tissue renin-angiotensin-aldosterone system in diabetes mellitus. Current Science Inc 6, 98–105 (2004). https://doi.org/10.1007/s11906-004-0083-8

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11906-004-0083-8

Keywords

Search

Navigation